Drug Treatment and Resistance

  • P. R. Donald


The treatment of tuberculosis in childhood has in the past rested upon the principles developed for, and applied to, the treatment of adult tuberculosis. Children have thus been considered as “therapeutic orphans” and treated empirically with regimens similar to those used in adults, but with some adjustment of dosages1.


Pulmonary Tuberculosis Tuberculous Meningitis Constrictive Pericarditis Antituberculosis Drug Tuberculosis Control Programme 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Smith MHD (1982). What about short course and intermittent chemotherapy for tuberculosis in children? Pediatr Infect Dis 1: 298–303PubMedCrossRefGoogle Scholar
  2. 2.
    Mitchison DA (1985). The action of antituberculosis drugs in short course chemotherapy. Tubercle 66: 219–225PubMedCrossRefGoogle Scholar
  3. 3.
    Mitchison DA, Dickinson JM (1978). Bactericidal mechanisms in short course chemotherapy. Bull IUATLD 53: 254–259Google Scholar
  4. 4.
    Sirgel FA, Botha FJH, Parkin DP, Van de Wal BW, Donald PR, Clark PK, Mitchison DA (1993). The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicro Chemoth 32: 867–875CrossRefGoogle Scholar
  5. 5.
    Grange JM (1990). Drug resistance and tuberculosis elimination. Bull IUAT 65: 57–59Google Scholar
  6. 6.
    Starke J (1990). Multidrug therapy for tuberculosis in children. Pediatr Infect Dis J 9: 785–793PubMedCrossRefGoogle Scholar
  7. 7.
    Biddulph J, Kokaha V, Sharma S (1988). Short course chemotherapy in childhood tuberculosis. J Trop Ped 34:20–23Google Scholar
  8. 8.
    Kumar L, Dhand R, Singhi PD, Rao KLN, Katariy S (1990). A randomized trial of fully intermittent vs daily followed by intermittent short course chemotherapy for childhood tuberculosis. Pediatr Infect Dis J 9: 802–806PubMedCrossRefGoogle Scholar
  9. 9.
    Lecoeur HF, Truffot-Pernot C, Grosset JH (1989). Experimental short course preventative therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 140: 1189–1193PubMedCrossRefGoogle Scholar
  10. 10.
    Hong Kong Chest Service, Tuberculosis Research Centre, Madras, British MRC (1989). A controlled trial of 3-month, 4-month and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Am Rev. Respir Dis 139: 871–876Google Scholar
  11. 11.
    Dutt AK, Moers D, Stead WW (1989). Smear- and culture- negative pulmonary tuberculosis: Four months short- course chemotherapy. Am Rev Respir Dis 139: 867–870PubMedGoogle Scholar
  12. 12.
    World Health Organization (1993). Treatment of tuberculosis. Guidelines for national programmes. Geneva: WHOGoogle Scholar
  13. 13.
    Chaulet P (1990/1991). Compliance with chemotherapy for tuberculosis. Responsibilities of the Health Ministry and of physicians. Bull IUAT Lung Dis 66 (Supplement): 33–35Google Scholar
  14. 14.
    Grzybowski S (1991). Tuberculosis in the third world. Thorax 46: 689–691PubMedCrossRefGoogle Scholar
  15. 15.
    Brudney K, Dobkin J (1991). Resurgent tuberculosis in New York city. Human immunodeficiency virus, homelessness and the decline of tuberculosis control programmes. Am Rev Respir Dis 144: 745–749PubMedCrossRefGoogle Scholar
  16. 16.
    Farer LS (1982). Chemoprophylaxis. Am Rev. Respir Dis 125:102–107Google Scholar
  17. 17.
    Lincoln EM (1950). Course and prognosis of tuberculosis in children. Am J Med 9: 623–632PubMedCrossRefGoogle Scholar
  18. 18.
    Rouillon A, Perdrizet S, Parrot R (1976). Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle 57: 257–299CrossRefGoogle Scholar
  19. 19.
    Wallgren A (1948). The time-table of tuberculosis. Tubercle 29:245–251PubMedCrossRefGoogle Scholar
  20. 20.
    Donald PR, Gent WL, Seifart HI, Lamprecht JH, Parkin DP (1992). Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence of dosage and acetylation status. Pediatrics 89: 247–250PubMedGoogle Scholar
  21. 21.
    Ellard GA (1984). The potential clinical significance of the isoniazid anetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle 65: 211–250PubMedCrossRefGoogle Scholar
  22. 22.
    Girling DJ (1982). Adverse effects of antituberculosis drugs. Drugs 23: 56–74PubMedCrossRefGoogle Scholar
  23. 23.
    Donald PR, Schoeman JF, O’Kennedy A (1987). Hepatic toxicity during chemotherapy for severe tuberculous meningitis. Am J Dis Child 141: 741–743PubMedGoogle Scholar
  24. 24.
    Kumar A, Misra PK, Mehotra R et al (1991). Hepatotoxicity of rifampicin and isoniazid. Am Rev Respir Dis 143: 1350–1352PubMedGoogle Scholar
  25. 25.
    Lorber J (1960). Treatment of tuberculous meningitis. Lancet 1:1309–1312Google Scholar
  26. 26.
    Kending EL, Burch CD (1960). Short-term antimicrobial therapy of tuberculous meningitis. Am Rev Respir Dis 82: 672–681Google Scholar
  27. 27.
    Strang JIG, Kakaza HHS, Gibson DG et al (1982). Controlled trial of prednisone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 2:1418–1422Google Scholar
  28. 28.
    Alzeer AH, Fritz JM (1993). Corticosteroids and tuberculosis: risks and use as adjunct therapy. Tubercle Lung Dis 74:6–11CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1995

Authors and Affiliations

  • P. R. Donald

There are no affiliations available

Personalised recommendations